Sensulin
Sensulin CEO and entrepreneur, always looking for the next great idea, co-founded several nanotech & medical companies (two acquired by DuPont & Wisepower).
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Series B | ||
| Total Funding | 000k | ||
Related Content
Sensulin is a preclinical biopharmaceutical company focused on developing glucose-responsive insulin for individuals with type 1 and type 2 diabetes. The company operates in the healthcare and pharmaceutical market, targeting patients who require insulin therapy. Sensulin's business model revolves around the research and development of insulin formulations that respond to glucose levels, thereby minimizing the risk of hypoglycemia and reducing long-term complications such as eye and kidney diseases. Revenue generation is anticipated through partnerships, licensing agreements, and eventual commercialization of their insulin products. The company's approach addresses a significant need in diabetes management by offering a more precise and responsive insulin therapy.
Keywords: biopharmaceutical, glucose-responsive, insulin, diabetes, hypoglycemia, complications, preclinical, healthcare, pharmaceutical, therapy